Aevis Victoria SA Stocks

CHF 13.15Last Updated 10.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CHF 1.41B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CHF 13.15
Key Takeaways

Risk factor

Significant default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aevis Victoria SA engages in healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. The company operates through Hospitals, Hospitality, Telemedicine, and Real Estate segments. It operates 22 hospitals with 1,496 beds; manages with a total of 941 rooms with a total rentable surface of 188,109 sqm. It also provides telemedicine, and ambulance and day clinic services. In addition, it engages in the patient hotel, better aging, radiology institute, pharmacy, ophthalmology, real estate management, stem cells, cosmetics, and publishing businesses, as well as organizes seminars. The company is headquartered in Fribourg, Switzerland. Aevis Victoria SA is a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of AEVS.SW is 17 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks